154_CD
GlaxoSmithKline_NN
Financial_NN
record_NN
Quarterly_JJ
trend_NN
An_DT
unaudited_JJ
analysis_NN
is_VPRT [BYPA]
provided_VBN
by_PIN
quarter_NN
of_PIN
the_DT
Group_NN
results_NN
in_PIN
sterling_GER
for_PIN
the_DT
financial_JJ
year_NN
2004_CD
._.
The_DT
analysis_NN
comprises_VPRT
statutory_JJ
results_NN
,_,
business_NOMZ
performance_NN
results_NN
and_CC
pharmaceutical_JJ
sales_NN
by_PIN
therapeutic_JJ
area_NN
._.
160_CD
GlaxoSmithKline_NN
Financial_NN
record_NN
Five_CD
year_NN
record_NN
A_DT
record_NN
of_PIN
financial_JJ
performance_NN
is_VPRT [PASS]
provided_VBN
analyzed_VBN
in_PIN
accordance_NN
with_PIN
current_JJ
reporting_GER
practice_NN
._.
Merger_NN
,_,
restructuring_GER
and_PHC
disposal_NN
of_PIN
subsidiaries_NN
Manufacturing_GER
and_CC
other_JJ
restructuring_GER
83 121 162 171_CD
Merger_NN
costs_NN
and_PHC
product_NN
divestments_NOMZ
286_CD
840_CD
1,069_CD
895_CD
Other_JJ
items_NN
21_CD
50_CD
421_CD
22_CD
Loss_NN
profit_NN
before_IN
taxation_NOMZ
390_CD
1,011_CD
1,652_CD
702_CD
Loss_NN
profit_NN
attributable_JJ
to_PIN
shareholders_NN
281_CD
712_CD
1,330_CD
452_CD
Business_NOMZ
performance_NN
results_NN
Turnover_NN
20,359_CD
21,441_CD
21,212_CD
20,489_CD
18,079_CD
R&D_NN
expenditure_NN
2,839_CD
2,770_CD
2,732_CD
2,555_CD
2,510_CD
per_PIN
cent_NN
of_PIN
sales_NN
14_CD
%_NN
13_CD
%_NN
13_CD
%_NN
12_CD
%_NN
14_CD
%_NN
Trading_GER
profit_NN
6,150_CD
6,904_CD
6,712_CD
6,041_CD
5,061_CD
per_PIN
cent_NN
of_PIN
sales_NN
30_CD
%_NN
32_CD
%_NN
32_CD
%_NN
30_CD
%_NN
28_CD
%_NN
Net_JJ
interest_NN
payable_JJ
203 161 141_CD
88_CD
182_CD
profit_NN
before_IN
taxation_NOMZ
6,119_CD
6,703_CD
6,535_CD
6,157_CD
5,362_CD
Adjusted_VBN
earnings_GER
profit_NN
attributable_JJ
to_PIN
shareholders_NN
4,302_CD
4,759_CD
4,642_CD
4,371_CD
3,686_CD
During_PIN
the_DT
years_NN
2000_CD
to_PIN
2003_CD
,_,
business_NOMZ
performance_NN
was_VBD [BEMA]
the_DT
primary_JJ
performance_NN
measure_NN
used_VBN [WZPAST]
by_PIN
management_NOMZ
and_CC
was_VBD [PASS]
presented_VBN
after_IN
excluding_VBG
merger_NN
items_NN
,_,
integration_NOMZ
and_PHC
restructuring_GER
costs_NN
and_PHC
disposals_NN
of_PIN
business_NOMZ
._.
Management_NOMZ
believes_VPRT [PRIV]
that_THVC
exclusion_NN
of_PIN
these_DEMO
items_NN
provides_VPRT
a_DT
better_JJ
comparison_NN
of_PIN
the_DT
way_NN
in_PIN
which_WDT [PIRE]
the_DT
business_NOMZ
was_VBD [PASS]
managed_VBN
and_PHC
gives_VPRT
an_DT
indication_NOMZ
of_PIN
the_DT
performance_NN
of_PIN
the_DT
Group_NN
in_PIN
terms_NN
of_PIN
those_DEMO
elements_NOMZ
of_PIN
revenue_NN
and_PHC
expenditure_NN
which_WDT [WHOBJ]
local_JJ
management_NOMZ
was_VBD [BEMA]
able_PRED
to_PIN
inuence_NN
._.
This_DEMO
information_NOMZ
,_,
which_WDT [SERE]
is_VPRT [PASS]
provided_VBN
in_CONJ
addition_NULL
to_PIN
the_DT
statutory_JJ
results_NN
prepared_VBN
under_IN
UK_NN
GAAP_NN
,_,
is_VPRT [PASS]
given_VBN
to_TO
assist_VB
shareholders_NN
to_TO
gain_VB
a_DT
clearer_JJ
understanding_GER
of_PIN
the_DT
underlying_VBG
performance_NN
of_PIN
the_DT
business_NOMZ
and_CC
to_TO
increase_VB
comparability_NOMZ
for_PIN
the_DT
periods_NN
presented_VBN
._.
Statutory_JJ
results_NN
include_VPRT
these_DEMO
items_NN
._.
For_PIN
2004_CD
,_,
with_PIN
the_DT
completion_NOMZ
of_PIN
these_DEMO
programs_NN
,_,
the_DT
Group_NN
is_VPRT
reporting_VBG [PUBV]
results_NN
on_PIN
a_DT
statutory_JJ
basis_NN
only_DWNT
._.
2004 2003 2002 2001_CD
2000_CD
Amounts_NN
in_PIN
accordance_NN
with_PIN
US_FPP1
GAAP_NN
m_FW
m_FW
m_FW
m_FW
m_FW
Turnover_NN
19,986_CD
21,117_CD
21,212_CD
20,489_CD
9,559_CD
Net_JJ
income_NN
loss_NN
2,732_CD
2,420_CD
413_CD
143_CD
5,228_CD
Basic_JJ
net_JJ
income_NN
loss_NN
per_PIN
share_NN
pence_NN
47.6_CD
41.7_CD
p_NN
7.0_CD
p_NN
2.4_CD
p_VPRT
145.6_CD
p_JJ
Diluted_JJ
net_JJ
income_NN
loss_NN
per_PIN
share_NN
pence_NN
47.5_CD
41.6_CD
p_NN
7.0_CD
p_NN
2.4_CD
p_VPRT
145.6_CD
p_JJ
The_DT
information_NOMZ
below_PLACE
presents_NN
US_FPP1
GAAP_NN
net_JJ
income_NN
loss_NN
and_CC
net_JJ
income_NN
loss_NN
per_PIN
share_NN
as_IN
if_COND
the_DT
results_NN
for_PIN
the_DT
years_NN
ended_VBN
31st_CD
December_NN
2000_CD
and_CC
2001_CD
were_VBD [PASS]
adjusted_VBN
to_TO
reverse_VB
the_DT
amortisation_NOMZ
expense_NN
for_PIN
goodwill_NN
and_CC
indefinite-lived_JJ
intangible_JJ
assets_NN
,_,
that_DEMP
is_VPRT
,_,
as_IN
if_COND
SFAS_NN
142_CD
had_VBD [SPAU] [PEAS]
also_RB
applied_VBN
in_PIN
those_DEMO
years_NN
._.
It_PIT
excludes_VPRT
those_DEMO
employees_NN
who_WP [WHSUB]
are_VPRT [PASS]
employed_VBN
and_PHC
managed_VBN
by_PIN
GlaxoSmithKline_NN
on_PIN
a_DT
contract_NN
basis_NN
._.
Exchange_NN
rates_NN
As_IN
a_DT
guide_NN
to_PIN
holders_NN
of_PIN
ADRs_NN
,_,
the_DT
following_VBG
tables_NN
set_VBN [WZPAST]
out_PIN [STPR]
,_,
for_PIN
the_DT
periods_NN
indicated_VBD [PRIV]
,_,
information_NOMZ
on_PIN
the_DT
exchange_NN
rate_NN
of_PIN
US_FPP1
dollars_NN
for_PIN
sterling_GER
as_IN
reported_VBN [PUBV]
by_PIN
the_DT
Federal_NN
Reserve_NN
Bank_NN
of_PIN
New_NN
York_NN
noon_NN
buying_NN
rate_NN
._.
Average_JJ
1.84_CD
1.63_CD
1.51_CD
1.44_CD
1.51_CD
The_DT
average_JJ
rate_NN
for_PIN
the_DT
year_NN
is_VPRT [PASS]
calculated_VBN [PRIV]
as_IN
the_DT
average_NN
of_PIN
the_DT
noon_NN
buying_NN
rates_NN
on_PIN
the_DT
last_JJ
day_NN
of_PIN
each_QUAN
month_NN
during_PIN
the_DT
year_NN
._.
